J A Batsis1, T A Mackenzie2, L K Barre3, F Lopez-Jimenez4, S J Bartels3. 1. 1] Section of General Internal Medicine, Department of Medicine, Dartmouth-Hitchcock Medical Center, Lebanon, NH, USA [2] Geisel School of Medicine at Dartmouth, Hanover, NH, USA [3] Centers for Aging and Aging Research, Dartmouth College, Hanover, NH, USA. 2. Geisel School of Medicine at Dartmouth, Hanover, NH, USA. 3. 1] Geisel School of Medicine at Dartmouth, Hanover, NH, USA [2] Centers for Aging and Aging Research, Dartmouth College, Hanover, NH, USA. 4. Division of Cardiovascular Diseases, Department of Medicine, Mayo Clinic, Rochester, MN, USA.
Abstract
BACKGROUND: Sarcopenia is defined as the loss of skeletal muscle mass and quality, which accelerates with aging and is associated with functional decline. Rising obesity prevalence has led to a high-risk group with both disorders. We assessed mortality risk associated with sarcopenia and sarcopenic obesity in elders. METHODS: A subsample of 4652 subjects ≥60 years of age was identified from the National Health and Nutrition Examination Survey III (1988-1994), a cross-sectional survey of non-institutionalized adults. National Death Index data were linked to this data set. Sarcopenia was defined using a bioelectrical impedance formula validated using magnetic resonance imaging-measured skeletal mass by Janssen et al. Cutoffs for total skeletal muscle mass adjusted for height(2) were sex-specific (men: ≤5.75 kg/m(2); females ≤10.75 kg/m(2)). Obesity was based on % body fat (males: ≥27%, females: ≥38%). Modeling assessed mortality adjusting for age, sex, ethnicity (model 1), comorbidities (hypertension, diabetes, congestive heart failure, osteoporosis, cancer, coronary artery disease and arthritis), smoking, physical activity, self-reported health (model 2) and mobility limitations (model 3). RESULTS: Mean age was 70.6±0.2 years and 57.2% were female. Median follow-up was 14.3 years (interquartile range: 12.5-16.1). Overall prevalence of sarcopenia was 35.4% in women and 75.5% in men, which increased with age. Prevalence of obesity was 60.8% in women and 54.4% in men. Sarcopenic obesity prevalence was 18.1% in women and 42.9% in men. There were 2782 (61.7%) deaths, of which 39.0% were cardiovascular. Women with sarcopenia and sarcopenic obesity had a higher mortality risk than those without sarcopenia or obesity after adjustment (model 2, hazard ratio (HR): 1.35 (1.05-1.74) and 1.29 (1.03-1.60)). After adjusting for mobility limitations (model 3), sarcopenia alone (HR: 1.32 ((1.04-1.69) but not sarcopenia with obesity (HR: 1.25 (0.99-1.58)) was associated with mortality. For men, the risk of death with sarcopenia and sarcopenic obesity was nonsignificant in both model-2 (HR: 0.98 (0.77-1.25), and HR: 0.99 (0.79-1.23)) and model 3 (HR: 0.98 (0.77-1.24) and HR: 0.98 (0.79-1.22)). CONCLUSIONS: Older women with sarcopenia have an increased all-cause mortality risk independent of obesity.
BACKGROUND:Sarcopenia is defined as the loss of skeletal muscle mass and quality, which accelerates with aging and is associated with functional decline. Rising obesity prevalence has led to a high-risk group with both disorders. We assessed mortality risk associated with sarcopenia and sarcopenic obesity in elders. METHODS: A subsample of 4652 subjects ≥60 years of age was identified from the National Health and Nutrition Examination Survey III (1988-1994), a cross-sectional survey of non-institutionalized adults. National Death Index data were linked to this data set. Sarcopenia was defined using a bioelectrical impedance formula validated using magnetic resonance imaging-measured skeletal mass by Janssen et al. Cutoffs for total skeletal muscle mass adjusted for height(2) were sex-specific (men: ≤5.75 kg/m(2); females ≤10.75 kg/m(2)). Obesity was based on % body fat (males: ≥27%, females: ≥38%). Modeling assessed mortality adjusting for age, sex, ethnicity (model 1), comorbidities (hypertension, diabetes, congestive heart failure, osteoporosis, cancer, coronary artery disease and arthritis), smoking, physical activity, self-reported health (model 2) and mobility limitations (model 3). RESULTS: Mean age was 70.6±0.2 years and 57.2% were female. Median follow-up was 14.3 years (interquartile range: 12.5-16.1). Overall prevalence of sarcopenia was 35.4% in women and 75.5% in men, which increased with age. Prevalence of obesity was 60.8% in women and 54.4% in men. Sarcopenic obesity prevalence was 18.1% in women and 42.9% in men. There were 2782 (61.7%) deaths, of which 39.0% were cardiovascular. Women with sarcopenia and sarcopenic obesity had a higher mortality risk than those without sarcopenia or obesity after adjustment (model 2, hazard ratio (HR): 1.35 (1.05-1.74) and 1.29 (1.03-1.60)). After adjusting for mobility limitations (model 3), sarcopenia alone (HR: 1.32 ((1.04-1.69) but not sarcopenia with obesity (HR: 1.25 (0.99-1.58)) was associated with mortality. For men, the risk of death with sarcopenia and sarcopenic obesity was nonsignificant in both model-2 (HR: 0.98 (0.77-1.25), and HR: 0.99 (0.79-1.23)) and model 3 (HR: 0.98 (0.77-1.24) and HR: 0.98 (0.79-1.22)). CONCLUSIONS: Older women with sarcopenia have an increased all-cause mortality risk independent of obesity.
Authors: Barbra S Miller; Kathleen M Ignatoski; Stephanie Daignault; Ceit Lindland; Megan Doherty; Paul G Gauger; Gary D Hammer; Stewart C Wang; Gerard M Doherty Journal: World J Surg Date: 2012-07 Impact factor: 3.352
Authors: John A Batsis; Karine R Sahakyan; Juan P Rodriguez-Escudero; Stephen J Bartels; Virend K Somers; Francisco Lopez-Jimenez Journal: Am J Cardiol Date: 2013-08-29 Impact factor: 2.778
Authors: Marjolein Visser; Stephen B Kritchevsky; Bret H Goodpaster; Anne B Newman; Michael Nevitt; Elizabeth Stamm; Tamara B Harris Journal: J Am Geriatr Soc Date: 2002-05 Impact factor: 5.562
Authors: V E Arango-Lopera; P Arroyo; L M Gutiérrez-Robledo; M U Pérez-Zepeda; M Cesari Journal: J Nutr Health Aging Date: 2013-03 Impact factor: 4.075
Authors: Soo Lim; Jung Hee Kim; Ji Won Yoon; Seon Mee Kang; Sung Hee Choi; Young Joo Park; Ki Woong Kim; Jae Young Lim; Kyong Soo Park; Hak Chul Jang Journal: Diabetes Care Date: 2010-05-11 Impact factor: 19.112
Authors: Ian Janssen; Richard N Baumgartner; Robert Ross; Irwin H Rosenberg; Ronenn Roubenoff Journal: Am J Epidemiol Date: 2004-02-15 Impact factor: 4.897
Authors: M C Kizilarslanoglu; M K Kilic; R T Dogrul; F Sumer; H D Varan; M E Kuyumcu; Y Yesil; M Halil Journal: Eur J Clin Nutr Date: 2016-02-24 Impact factor: 4.016
Authors: A Spahillari; K J Mukamal; C DeFilippi; J R Kizer; J S Gottdiener; L Djoussé; M F Lyles; T M Bartz; V L Murthy; R V Shah Journal: Nutr Metab Cardiovasc Dis Date: 2016-06-28 Impact factor: 4.222
Authors: J M Brooks; A J Titus; M L Bruce; N M Orzechowski; T A Mackenzie; S J Bartels; J A Batsis Journal: J Nutr Health Aging Date: 2018 Impact factor: 4.075